EYPT - Earnings call transcript Q3 2018 | EyePoint Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Third Quarter Fiscal 2018 EyePoint Pharmaceuticals Earnings Conference Call.

As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference Barbara Ryan with ‎Barbara Ryan Advisors. Ms. Ryan, you may begin.

‎Barbara Ryan

March good review joining third corporate EyePoint for period and call on quarter developments. operator, well the to as today Pharmaceuticals ending you, afternoon review us everyone the results as Thank to XXXX, recent XX, fiscal XXXX Chief Vice Making and President and Accounting today's Officer. of Pharmaceuticals' on Len and remarks are Nancy Finance Officer; prepared EyePoint Ross, Lurker, call President Executive the company's Principal

fact, other I'd or begin, you to considered than we statements and like or historical anticipated other or results statements, we Before implied realized. that cannot of materially differ projected will anticipated, remind could from are expressed, the estimated statements the forward-looking in be statements. all guarantee results those Actual expectations forward-looking

statement detailed reflect call our The Officer, over of It Pharmaceuticals' no can to pleasure Lurker. the is with we discussion financial turn in call. conditions, update the that and factors Chief report to future XX-K. company President order now conference circumstances any annual you its events that and on more to to Pharmaceuticals' arise impact refer risk this to Nancy forward-looking Form my SEC, undertakes For EyePoint filings after may Executive results a or EyePoint obligation including

Nancy Lurker

Thank a operating you, highlights, anticipated for review Barbara, and third you and financial for good recent results, afternoon, of us fiscal joining everyone. Thank quarter our XXXX milestones.

as transformative ophthalmology. and we number executed have on specialty on never greater prospects Gregg quarter Advisor; to we company Len, Beloff, knew XX In Dario accelerate we a Financial basic ago, over value. been of this joined my Chief the are drive the significant elements Chief has transition When months addition to to had shareholder I commercial-stage Medical enthusiasm company and pharmaceuticals successful focused the joining afternoon during me Paggiarino, and will a growth level company, that build excitement Officer. I our a Today, of milestones as

For those level me transformational review new EyePoint developments. a story, let at to the high these

Bioscience. the and steroid FDA inflammation. First, are Icon's ocular February the approved there single X on of opportunity surgery treatment We approved end and administered it's cataract the by surgery Icon FDA the intraocular following in as inflammation long-acting March the large, growing. was for million first treatment the the at is DEXYCU is for year injection DEXYCU, by product, United surgeries a privately-held as X. believe States lead quite post-operative XX, intraocular cataract we the each for on acquired DEXYCU commercial of approximately

bioerodible days month, X impairment steady to in surgeon highly the up for extremely it at is a on a these administers XX comparison, hands. cognitive are a patients fully challenging, single of as post-surgery regimen confusing, a and one may drops schedule This these administering simply release arduous the we steroid difficult inflammation make elderly the physicians, who Many over to Let represents go By a into who for There Verisome administer are as physicians or steroid number technology over weeks. for encapsulated their injection daily DEXYCU surgery, osteoarthritis more me and perform current surgery unmet treat explain can of The who up fully eliminate of them. of the the care major DEXYCU. of end period such of of physicians and a is to titrady cataract have to and standard patients for patients an conditions again, requiring patients need the medical among of regimen and of confusing. drug dexamethasone the that XX a in detail drop why health eye-drop lengthy high [ph] advance need undergo which microliters provides excited a and about days.

Our team of market to highly opinion known and cataract with drugs existing upcoming a intent several DEXYCU dosing Further, where of as the known as patient Physicians both advance care new Cataract as commercial DEXYCU we very research steroid The Vision data. about consistently the over and launch the ARVO, stated surgery of surgeons. of bolsters recently the DEXYCU in address high safety consistently post familiar Surgery, to potential has after use regimen its were becoming meetings. anticipated physicians of the drop a Research The confidence held and otherwise excited Society our treatments, and innovative surgery few otherwise Refractive boards American our of advisory and attended ASCRS, for Association frustrating Ophthalmology, and in efficacy in particularly has numerous cataract positive had highly DEXYCU. physician advance And is cataract eye-care. field and

patients turn surgery me B. let reimbursement. by Now, are Part cataract undergo who to majority The of Medicare covered

level, cataract provision price payment. designed are an reimbursement surgery bridge it's overall to for to under scheme. center's The is by New not facility of of established pass-through payment covered on at drugs payment called pass-through a is procedure the are of transitional pass-through paid regular ambulatory FDA, insignificant referred payment transitional, of innovative a part cost development. consists into a priced which to reimbursement to approved and the Congress relative drug what fee. be because surgical This the This foster was as the by drug, are top the Medicare Congressional

Code qualifies transitional under lasting three a reimbursed Code. for such, be quarter C called a $XXX and dose. will price to pass-through issued as years is is status the So C Medicare CMS. minimum of approximately before we expect per the pass-through are Codes required product regulation, for C this DEXYCU what a launch. file Under is at payment. temporary, shortly And we to by DEXYCU

that to due that, and final at normal given lose don't to and inadvertently than higher fact be pricing will fall not determined or yet not the $XXX discounts time. to we this payers. have modestly status, rebates to providers we to than this want commercial We Other do ensure price below pass-through it due

use to, patients be utilization. $XXX status into pass-through most cases, potential result market years, in estimate and no million DEXYCU's of million, the we We eliminated a period. the strong cataract bundled and physicians to As DEXYCU to DEXYCU system. the is pass-through longer incorporated reimbursement After to steroid enjoy the expect DEXYCU ability three drops, scheduled to status and for be $XXX status during pass-through three-year is payment to allow

extension underway bill as passed recent work have have Icon, already of Congress two the status part to XXXX. the at pass-through There recently this to in achieved we a few by spending least a bill years. However, transitioned for drugs for omnibus pursuant DEXYCU's extend as extension precedent is March another by

will However, there guarantee this is we no able extension. to get be

in and the involved separate innovative for patent surgery continue ability for In drugs efforts addition, DEXYCU longer would patented of life, to cataract reimbursement to then including DEXYCU to a from allow the all almost drugs. we it This these as fee. actively for payment bundled fee physicians the are is use continue for a time, potentially case bundled reimburse outside other through period of cataract

eye global On opportunity method additional citrate, of treating allowance we're These of acetyl as posterior investors DEXYCU very keep these pleased and amounts following to the IP small further including to the two We related delivering of cataract the treatment DEXYCU from a inflammation syringe. respectively. our claims portfolio progress. believe issued of notices out an fronts our on our year of for by continue with surgery, note, and dexamethasone, dose for April, was strengthened uveitis. XXXX small claims another new patents to delivering for extremely efforts three triethyl XXXX complements a product go patents, and treatment volume informed loading segment in will injection that two to We related YUTIQ,

position potential commercial review to of Our XXXX and the approval date. FDA leverage regulatory YUTIQ and will organization November building. has NDA first by plus a launch products for we half is are of DEXYCU of YUTIQ the launch under PDUFA The two XXXX significantly the us in X, the

and the meeting. or on Research We weeks recently Ophthalmology present date at annual ARVO's continue as to ago for positive in Association YUTIQ, Vision two

from We Holdings. a term also sheet SWK $XX third million commitments to balance to our up up strengthened with Woodlands and $XX.X the from loan in Essex quarter capital million during of Healthcare

tranche EW ramp strategy. Healthcare meeting. up on subject XXXX, and shareholder look a and for their substantial to build and launch on our investment the highly we June EW give is a the vote to a at powerful the of These up and financial XX, investment the is endorsement shareholder second YUTIQ. voting a is team commercial capability Healthcare firm, investment and forward DEXYCU us of prospects The respected to your resources

we may addition, come will that remain In about additional way. opportunistic opportunities our

joined of sustainable from growth These as and our to multiple game And constituents Healthcare EW gain at Director we the execute building Managing a will Eastman, to healthcare highly continue ophthalmology from has with experience are his years in Ron the build changing. have accomplishments companies, we positive. all feedback initiatives immediately XX received we insight, been on company. Additionally, board

important how So planning have achieved transaction what the review this it's we're both launch time, well-executed to we at I a think and since for for products.

will strategy our ensure we success. implement to four First, pillar

to highly and begin at to to finalizing have the seasoned a close sales fully organization laying trained premier organization, agreement field with well-established a and CSO intend and We a we are groundwork launch. contract

while the success ensure organization, efforts commercial pillar and enhance the consist implement plan, market medical strategy to continuing to ongoing initiatives. progress four education Our our program access of our marketing sales to

a who numerous achievement VP For a of Marketing, we've with is executive commercializing launching example, ophthalmology proven hired and brand. of record

launches ophthalmic space. Medical hired multiple also Head Affairs record track have of the a in with We supporting successful

and education ARVO, our to at We heightened by such medical and in medical strategy. publication are as our already of congresses abstract implementation executing addition on evidenced presence as ASCRS

surgery to highly market models. of the we buy-and-billed] expect with we ahead mind have of experienced shortly, access, and reimbursement candidate [ph] in center is market for and As strong hire access [grasp

YUTIQ. call pre-marketing On I number pillar attract upcoming the down over coming I performance, personally financial preparing been very we've I'll we the Ross marketing and excited another highly road our been of a we and These turn activities four months, With significantly finalizing company. I'll Len? large look the for - our that, for other over about And the able our updates giving milestones. the for the launched. for to associated DEXYCU on initiatives personal marketing as then EyePoint initiatives our our review strengthen positioned of Len are I'm successful and pre-marketing on quality strategy. to high success. to commercial additions team, review to with have forward of initiative, key the for well a you

Len Ross

prior the Nancy, the for was third today's Revenue quarter. fiscal everyone. fiscal results we that compared briefly close. ended to $XXX,XXX Thank $XXX,XXX good will for XX, following and quarter I afternoon quarter review year XXXX third our to you, March reported

$X.X in to EW of slightly year current were speak $X.X $X.X Our loss net liability of loss third decreased Revenue March earlier, $X.X the Included for primarily per by XXXX. of this quarter. XX, was from and higher increased change months stock-based nine the to non-cash or charge personnel due in for in million a few the expense, offset or related investment. expense related period Net XXXX and YUTIQ representing non-operating lower months XXXX year to to share, to March million moments. prior support quarter further ended $X.XX and operating consulting non-cash million compared expenses the per costs I $X.X tranche a $X.X to the clinical fair regulatory services partially a in compensation the for loss in nine compared March ended for XX, value expenses. a to trial second charge share, million, was XX, Healthcare million net $X ended and the derivative quarter for $X.XX million of million, clinical will

of development the agreement. deferred from of included and totaling million resulting revenue our As year period noted $X.X previously, recognition collaboration Pfizer the the termination research prior collaborative

$X.X Net Operating period. our ended XXXX the nine Pfizer, a the fiscal the earlier. revenues $X.XX for or per with compared end months approximately of year from expenses per of stock equity Icon to common first the for XX, first year a proceeds $XX.X prior of and the months million million for EW $XX.X shares for Excluding of the fiscal Healthcare, million period. tranche the quarter year million gross XX, facility XXXX approximately million conjunction also XXXX March ended new $XX loan third with million months for or a nine we $X.X of net the borrowed loss $XX.X nine million through term Holdings. compared SWK XXXX investment under issued XXXX X.X was corresponding acquisition, to $X.XX to loss Bioscience share of for fiscal were compared $X.X million $XX.X in million period share At were March

warrants expected and second the of proceeds consisting company of for well share from exercise of an units meeting warrant of million to with SWK The stock gross are as one purchase term The would the include will financing approved, special tranche drawdown If second the a does million approximate of the have six for stock received is derived to equity additional investment purchase facility. common an this million approximately of of in EW tranche approval, share XX, $XX.X of subject million proceeds Healthcare common scheduled under a loan months. stockholder to one tranche These second the additional as the of to upon $XX.X $XX.X $X with June not the XXXX. stockholders be each approximate the and would unit such that ability approximately result of warrants. be

For issue units value The liability must obligation accounting be to value to future at on March a transaction XX, purposes, date. in re-measurement the in fair fair the reporting alluded charge, million XXXX, and the company's at earlier. second $X.X of sheet, requires I non-cash as each balance to re-measurement resulted the recorded tranche

month was the million, common March of cash XX, and three of total periods nine outstanding At a number equivalents totaled March XX, each shares XXXX. million. XXXX, For and XX, cash at $XX.X ended March $XX.X

net totaled compared $X million to approximately net range quarter, to for commercial of if to anticipate in DEXYCU our launch used fiscal quarter. over second turn by the between to the the comments. now FDA $X.X operations million $X.X company's third readiness fiscal million the currently in back used from from million cash cash $X.X closing operations We her I and fourth quarter for as call the will we advanced YUTIQ. the Nancy approved During

Nancy Lurker

Len. Thank you,

in shareholder near-term the for questions, gain the half gain favorable and to conferences approval investment milestones. tranche meeting review launch four-pillar scientific including in YUTIQ me DEXYCU Vancouver first XXXX our at FDA the by we PDUFA at the summary, to YUTIQ, the year June present Specialists implement Retina continue July excellent significant first action American in of meeting; XXXX. in approval take XX commercialization at let the through we for second business November make and preparations Before executing of Society annual of work YUTIQ by the of for on EW Healthcare reimbursement These with the XX, our progress, include, including X medical subject pass-through XX; collaboratively calendar to In regulatory plan; its XXXX. regulatory secure approval plan, date; the DEXYCU; commercialization data YUTIQ half of U.S. companies DEXYCU leading

Pharmaceuticals Importantly, take Operator, forward on to progress. ready for keeping successfully EyePoint of we're capitalized, necessary with we you vote time is we and well are a a to very informed favorable now the resources now our assuming launch to questions. shareholder and YUTIQ. This June DEXYCU exciting XX, look

Operator

first François Brisebois Thank you. Instructions] from And question with our Laidlaw. [Operator comes

Your open. is line now

François Brisebois

Hi, thanks questions. for taking the

you so in hires made here, couple of timing the can about And terms a bit a recently? you build-out us the just organization? can of you experienced repeat, the the of little talk Just that then, sales help

Nancy Lurker

contract CSO, sales soon with Yeah, to organization. agreement so, an a are we sign Frank,

to is we move to Now, work lot laid, we are groundwork needs to again, when be that, launch back-office we that decide needs but will done that that ready so be will a slowly there - with that and to go. of

national an well initiated a for already director. close to that. as we've sales extending offer We're So

marketing. mentioned, hired a we've I've VP of As

head and of has soon been a That join person very the access to market company. identified start. expect ready to already We

start. head We of have which several MSLs, to a again, the medical for and MSLs affairs, is responsible ready

by - So again, reps, fully expect we district built-out a that we commercial except have won't to which call, those identified. earnings infrastructure our sales next have for begin will people more and managers we'll I

on launch until DEXYCU's November a commercial or for we launch, pull depending DEXYCU getting those not for or in YUTIQ trigger timing supplies cost positive ready the with and will approval obviously, FDA those case, to people, hopefully on YUTIQ, We are either XXXX.

François Brisebois

contrast or then, remind landscape, and physicians the process and you could and compare DEXYCU excellent. for terms Okay, competitive just us, educating of in the challenges YUTIQ of both products. And the terms in

Nancy Lurker

me with Yeah, amount pharmacies. small non-branded. I and okay, are there right drops, again, let on because used viable in caused the lawsuits, parts being There so that, led so the they problems problems, or been are the highly road. both FDA the where are of today as And problematic. by There country contaminated. steroid don't used is those the they are - first approved. what's some talk you unfortunately eye compounded down And now, DEXYCU. they've a market doctors about have multiple been only want not very, they've in blindness, some to branded being very go that's most But majority today. It's imagine serious DEXYCU of can that drugs compounded incidences real vast competitors cases, the to

So right in There and unbranded really these one now the today, steroid majority review. drops. vast are competitor it's is - branded

As their available them. is in currently re-filed for has the what's to be FDA. But only plug want I speak know what's don't Therapeutix up DEXYCU. you That's primarily punctal you a certainly terms may for waiting can with status. look that Ocular of to them -

available uveitis, eyesight who is HUMIRA one to blindness have me let threatening me to corticosteroids cost of patients reiterate, very inhibitors corticosteroids. they'll inflammatory numerous used corticosteroids. majority systemic segment so as a approximately right and an eye clarify, HUMIRA, vast such the as patients $XX,XXX $XX,XXX small And the by mentioned disease work. progressive. generic that's again, exception that's a the extremely that only As VEGF with posterior being works disease, a case, for this you which are the only the uveitis, conditions, the treated is today concomitant serious I've not side with And of systemic. are arthritis very, let for kinds And now is cause That know, other past, and typically uveitis, in of segment uveitis, YUTIQ, has again, of of effects. way, all which for thing it's are treating in as rheumatoid do leading the third the And But serious. as example. year back

where available, available believe which Retisert, which corticosteroids generic the What today. So cases. available are the and bioerodible chronic a OZURDEX, in It treatments doses lifelong it's to procedure corticosteroids, are lasts does there for condition in months. can YUTIQ require two advantages have of a - is of IOP. you tends have and to higher implant our cause is higher tend elevation specific is Retisert course, then, I'm is to that released used, And and three we that to are condition, technology. surgical to uveitis, most is that

is what your flares, begin you when because slowly to want prevent so, And do lose flares to occur, sight. eye you

result, And day as a delivered up flares. a dose to for single over the prevent meaning with corticosteroids only on advantage you The mentioned end low is longer consistent three do thing provides, three So a it's YUTIQ - years. you from known the those those as of release, flares with order to prevent I've at what dose, of micro category every gives every single it want years protection HUMIRA. zero very the small and flares, is day

the administered this big Now again, the another injection Doctor's that's - an we doctor's disclosure, advantage, obviously it's office. and office in full is in in

that slight can that the safety ability in balance, you. So - issues. some recurrences and prevent of cause is, potential for do also corticosteroid also we known again elevation fair cause we IOP, covers other side it effect But uveitis. of and YUTIQ and we advantage I it's hope long-term to believe

François Brisebois

the a and there? plan helpful. shorter-term that That's potential very of still absolutely. the filing of is idea going Yeah, then, sNDA in in for And just approval, the maybe

Nancy Lurker

for short-acting. our That's

YUTIQ. pipeline once the would that we And So these in an file get is years. plan our for the for current uveitis, approval short-acting sNDA that we as is three

as be YUTIQ, options. drug So have that for six doctor's, categories to that we because want month all able to a dose effective want And of in provide them. multiple dosing we

François Brisebois

me. Okay, great. Thank That's you for very much. it

Nancy Lurker

Thank you.

Operator

you. Thank

comes with next Andrew from FBR. Our D'Silva Riley B. question

open. now is line Your

Nancy Lurker

Andrew. Hi,

Andrew D'Silva

Hey, you? good afternoon. How are

Nancy Lurker

good. Very

Andrew D'Silva

the just hopping thanks right. But, for my can I'm based please All taking me so any you in also for And a I that, if And if and what between have related ones know, status here. next questions. what you actually few DEXYCU? memory call, my apologies if very the steps could just touched this. sorry, to my there you you on refresh was obtain Well, are let already quick I on touch related please advance, pass-through are are opinion? for hurdles to

Nancy Lurker

so. Yeah, I am happy do to

main and the an a simply there timeframe. pass-through basis so a file is set you quarterly are issue rolling quarterly mentioned the So on application. Codes issued basis, the rolling actually I on submitted C are quarterly code, then applications as is And the

So give then are expect, C be example. supply I'll us when that code confident we apply the we the an would would step enough and have next for for we will commercial produced, we

to able you in give to codes an in want submit need September, January, be you For then be will you application issued to and just affective to January, launch in C if instance, December, those code your example.

- why by to an C to And have pass $XXX product complicated - of would price there's by ensure in your insignificant the the pricing. there a couple you we device, and already you test at that you So have obviously formula then that's per insignificant submit pricing, price the not we're you will approved to not not pass. be pass there's that get although, a in and have buckets confident to code, then our that devices. cost for minimum one, have drug, We this go in qualify, dose. FDA. or know case have that the the tests. is that Number to in to you your a the somewhat applications that why very those Number that is NDA very, I have a And To that. to separate through and have are NDA, order two, that's we of plan, a you're approved that test. Those big said, a test we to

You have be and not in price you or receive your a to said. there quite few will and is things, that other cost the we're begin confident, are we insignificant point the minor And code. test, C achieve pass to this

Andrew D'Silva

to and Great. there. was color in obviously Icon. uveitis of great over a financing through progress And market the then, the awarded That you acquisition moving you've just for made the front, has the

part Now, as Healthcare. [ph] mentioned funding the EW the of] you of conscious [tied to with acquisition

prior I a tranche, with common particular $X.XX. bracketed, believe. believe as the to you and tranche first it's of the warrant I $X.XX it received to raise around tranche, somewhere the I shareholder with vote. second and second the on [ph] But set $X.XX, max stock, mentioned acquisition believe The requires equity the price And the is portion around

restrictive a feeling far path you it go with more covenants there are down And tranche? to that now now, that you eclipsing first price capital through actually took down sense the traditional go Can are rate essentially, that make or you able share does to path? So means? right

Gregg Beloff

of set to is this question. good is transform we organization. that I think this we a But Beloff. commercial Gregg a out to think way this, from It's the question. company I'll Thank do an So it that R&D very take you.

start you stock the was that how commitment the to stepped found allow the amount we made not the has they and relative significant release if appreciated of was at And fair And the imagine not is recall, as been, SWK. needed dilutive to with capital a - to it of the have One us financial EW, that the a of us our Essex we stock we - and sponsor. value and value to recently sponsors they stock. at And we to you things Woodlands value process, and as financial mentioned time, up price. as what dilutive at endeavor on was time, this this a believe we or could to certainly track be two the

if any we following And we as what's they issue to you think and we don't that to committed on our So commitment struck vote. to in deal really the previously the don't the is, have alternative have them with if about with fact, and shareholder that, get us.

We have way into capital that's market to do. something to a open out not the regular we're subject equity raise, and of go and to willing vagaries market variability's broad

Andrew D'Silva

rewarded enough. the I deal for up. was Fair set tranche obviously, Okay. just curious, market all you guys is getting establishing the the and

just was I want… So

Nancy Lurker

Andrew, let me just interject.

with Essex transactions. mentioned to another about to opportunities other highly to also I and for So think potential investors is I I've as Gregg us. additional we point, backing which long-term want it's are remain to also there for to opportunistic committed add made, important the understand, is And which that in addition intend those they the points excellent

Andrew D'Silva

my that last actually gives question. Okay, well, a segue into perfect

from beginning bases. the commercial two scenario, in effectively next have two the And So in a in of I physician and targeting, separate teams two year. blue sales what you'll approved market sky products understand

where it in-license does have make you doesn't you Now, that additional a for or point, from to to least utilization sense sense do make this at to force necessarily near-term to enough or at wood look acquiring chop increase standpoint? offerings sales

Nancy Lurker

just Well, this. let me say

chop of to have We DEXYCU plenty and YUTIQ. with wood

marketplace. that fragmented this marketplace fragmented as ophthalmology continue that further - to opportunities is and and you at opportunities to highly in the particular However, believe drive additional in shareholder there are we value looking and

sense. if opportunities. continue So to to to do at going to additional them we're open not will look remain we going Obviously, we don't But are opportunities. they make additional

Andrew D'Silva

Got it.

color luck perfect. congratulations of all thank for and the you've going you best Okay, made And forward. and on then the progress

Nancy Lurker

Thank you.

Operator

question Thank Yi from Instructions] our you. Chen comes with Wainwright. next And H.C. [Operator

Your now line open. is

Nancy Lurker

Yi. Hi,

Julian Harrison

there. Julian this This Hi, is - hi, Yi. on for

Nancy Lurker

Oh, hi.

Julian Harrison

Hi, to for NDA was since the about you the able you've had any with Are YUTIQ dialog there. submitted? talk FDA,

Nancy Lurker

time. be this at not wouldn't appropriate. It No,

discussion. Thank for just of We're review. in though. it. our As to appropriate you the of can imagine, the we're us for it's asking discuss middle NDA you in not And middle

Julian Harrison

Sure… Okay.

Nancy Lurker

me reassure we And then, time let will. you, the absolutely appropriate at

Julian Harrison

Okay. And any there second updates uveitis. been curious just for for posterior was question, have with segment if my recent short-acting I Durasert our

Nancy Lurker

study. comment. nicely our to in me continues Let It just bioequivalency do

So we our with plan track execute on that. are to

Julian Harrison

would for that general be steps program? your And with what associated next timeline

Nancy Lurker

an short-acting, mentioned expect That we in I assuming approval approval - we would expect But sNDA assuming earlier, first again XXXX. sometime once as in for to half is in of the NDA November. get get with would to we approved, file November. approval the file we we it's Yeah, get sNDA YUTIQ the once

Julian Harrison

taking great. my Okay, for you questions. Thank

Nancy Lurker

You're welcome.

Operator

you. this to now the Nancy to I'm turn I no further time, further and Thank for President At Lurker, any like CEO back questions. showing would remarks. conference

Nancy Lurker

I you to progress look Pharmaceuticals. to plan your and our EyePoint forward for exciting much. on the keeping investors the support for and time very to of exciting against opportunities for to I in taking Thank you listen all thank significant apprised, our we ahead very our as conference And make want call. executing months

Operator

Ladies gentlemen, this concludes and today's program.

Everyone, You a day. have may great disconnect. all

EyePoint Pharmaceuticals (EYPT) 8 May 182018 Q3 Earnings call transcript